Long-term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-up Data from a Three-year Open-Label Extension Study
Article in JID Innovations (September 2024)